# Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

> **NCT06102005** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 685 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Lunsekimig
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06102005
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-16
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-03-11
- **Target enrollment:** 685 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06102005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06102005, "Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06102005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*